Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
SEMA6B Biologics Sequence Review Report 2026: Semaphorin-6B Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
SEMA6B Biologics Sequence Review Report 2026: Semaphorin-6B Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of SEMA6B protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
SEMA4D Biologics Sequence Review Report 2026: Semaphorin-4D Similarity and Patent-Risk Signals
8 min read
SEMA4D Biologics Sequence Review Report 2026: Semaphorin-4D Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of SEMA4D protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
SEMA4G Biologics Sequence Review Report 2026: Semaphorin-4G Similarity and Patent-Risk Signals
8 min read
SEMA4G Biologics Sequence Review Report 2026: Semaphorin-4G Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of SEMA4G protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
SEMA4B Biologics Sequence Review Report 2026: Semaphorin-4B Similarity and Patent-Risk Signals
8 min read
SEMA4B Biologics Sequence Review Report 2026: Semaphorin-4B Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of SEMA4B protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
SEMA4A Biologics Sequence Review Report 2026: Semaphorin-4A Similarity and Patent-Risk Signals
8 min read
SEMA4A Biologics Sequence Review Report 2026: Semaphorin-4A Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of SEMA4A protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
SEMA3G Biologics Sequence Review Report 2026: Semaphorin-3G Similarity and Patent-Risk Signals
8 min read
SEMA3G Biologics Sequence Review Report 2026: Semaphorin-3G Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of SEMA3G protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
SEMA4C Biologics Sequence Review Report 2026: Semaphorin-4C Similarity and Patent-Risk Signals
8 min read
SEMA4C Biologics Sequence Review Report 2026: Semaphorin-4C Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of SEMA4C protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
SEMA3F Biologics Sequence Review Report 2026: Semaphorin-3F Similarity and Patent-Risk Signals
8 min read
SEMA3F Biologics Sequence Review Report 2026: Semaphorin-3F Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of SEMA3F protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
SEMA3D Biologics Sequence Review Report 2026: Semaphorin-3D Similarity and Patent-Risk Signals
8 min read
SEMA3D Biologics Sequence Review Report 2026: Semaphorin-3D Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of SEMA3D protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
SEMA3E Biologics Sequence Review Report 2026: Semaphorin-3E Similarity and Patent-Risk Signals
8 min read
SEMA3E Biologics Sequence Review Report 2026: Semaphorin-3E Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of SEMA3E protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
SEMA3C Biologics Sequence Review Report 2026: Semaphorin-3C Similarity and Patent-Risk Signals
8 min read
SEMA3C Biologics Sequence Review Report 2026: Semaphorin-3C Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of SEMA3C protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
SCARF1 Biologics Sequence Review Report 2026: Scavenger receptor class F member 1 Similarity and Patent-Risk Signals
8 min read
SCARF1 Biologics Sequence Review Report 2026: Scavenger receptor class F member 1 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of SCARF1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →